Benign prostatic hyperplasia - The result of an age-dependent alteration of the androgen-estrogen balance?;Die benigne Prostatahyperplasie - Das Ergebnis einer altersbedingten Entgleisung der Androgen-Estrogen-Balance?

Urologe - Ausgabe A

Volumn 36, Issue 1, 1997, Pages 3-9

  Weisser, Heike ^a,b   Krieg, M ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

aging; androgen metabolism; BPH; estrogens

Indexed keywords

ANDROGEN; ESTROGEN; FINASTERIDE; STEROID 5ALPHA REDUCTASE;

AGE; ENDOCRINE DISEASE; HUMAN; MALE; PROSTATE HYPERTROPHY; REVIEW;

AGED; ANDROGENS; EPITHELIUM; ESTROGENS; HOMEOSTASIS; HUMANS; MALE; PROSTATE; PROSTATIC HYPERPLASIA; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0031042844     PISSN: 03402592     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001200050060     Document Type: Review

References (28)

1. Walsh PC (1984) Human benign prostatic hyperplasia: etiological considerations. In: Kimball FA et al. (ed) New approaches of the study to benign prostatic hyperplasia. Liss, New York, pp 1-25
2. Grayhack JT (1992) Benign prostatic hyperplasia. The scope of the problem. Cancer [Suppl] 70: 275-279
3. Glynn RJ, Campion EW, Bouchard GR, Silbert JE (1985) The development of benign prostatic hyperplasia among volunteers in the normative aging study. Am J Epidemiol 121: 78-90
4. Bach D, Brühl P (1995) Epidemiologie, Ätiologie, Pathogenese und Symptomatik der benignen Prostatahyperplasie. In: Sökeland J (Hrsg) Benigne Prostatahyperplasie. Epidemiologie, Ätiologie, Pathogenese, Symptomatik, Therapie und Gesundheitsökonomie. Thieme, Stuttgart New York, S 2.1-2.9
5. Berry SJ, Coffey DS, Walsh PC, Ewing LL (1984) Development of benign prostatic hyperplasia with age. J Urol 132: 474-479
6. Ekman P (1989) BPH epidemiology and risk factors. Prostate 2 [Suppl]: 23-31
7. Wilson JD (1980) The pathogenesis of benign prostatic hyperplasia. Am J Med 68: 745-756
8. Coffey DS, Berry SJ, Ewing LL (1987) An overview of current concepts in the study of benign prostatic hyperplasia. In: Rodgers CH (ed) Benign prostatic hyperplasia, vol.II, NIH publication No. 87-2881, Bethesda, pp 1-13
9. Krieg M, Tunn S (1990) Androgens and human benign prostatic hyperplasia (BPH). In: Nieschlag EH, Behre HM (eds) Testosterone: Action, deficiency, substitution. Springer, Berlin Heidelberg New York, pp 219-244
10. Takeda H, Lasnitzki I, Mizuno T (1986) Analysis of prostatic bud induction by brief androgen treatment in the feal rat urogenital sinus. J Endocrinol 110: 467-470
11. Cunha GR, Donjacour AA, Cooke PS, Bigsby RM, Sugimura Y (1987) Stromal factors in the development and control of growth in the prostate. In: Rodgers CH (ed) Benign prostatic hyperplasia, vol.II, NIH publication No. 87-2881, Bethesda, pp 15-25
12. Krieg M, Horst HJ, Sterba ML (1975) Binding and metabolism of 5α-androstane-3α, 17β-diol and 5α-androstane-3β.17β-diol in the prostate. seminal vesicles and plasma of male rats: Studies in vivo and in vitro. J Endocrinol 64: 529-538
13. 3, steroid metabolite in the rat ventral prostate: 5α-androstane-3β, 6α, 17β-triol. Steroids 33: 639-657
14. Isaacs JT, McDermott IR, Coffey DS (1979) Characterization of two new enzymatic activities of the rat ventral prostate: 5α-androstane-3β, 17β 6α-hydroxylase and 5α-androstane-3β, 17β 7α-hydroxylase. Steroids 33: 675-692
15. Karaburagi Y, Marino MB, Kirdani RY, Greco JP, Karr JP, Sandberg AA (1987) The possibility of aromatization of androgen in human prostate. J Steroid Biochem 26: 739-742
16. Bartsch W, Klein H, Stürenberg HJ, Voigt KD (1987) Metabolism of androgens in human benign prostatic hyperplasia: Aromatase and its inhibition. J Steroid Biochem 27: 557-564
17. Tunn S, Claus S, Schulze H, Braun B-E, Krieg M (1987) 5α-androstane-3β, 17β-diol hydroxylating enzymes in stroma and epithelium of human benign prostatic hyperplasia (BPH). J Steroid Biochem 28: 257-265
18. Tunn S, Hochstrate H, Grundwald I, Flüchter StH, Krieg M (1988) Effect of aging on kinetic parameters of 5α-reductase in epithelium and stroma of normal and hyperplastic human prostate. J Clin Endocrinol Metab 67: 979-985
19. Tunn S, Haumann R, Hey J, Flüchter StH, Krieg M (1990) Effect of aging on kinetic parameters of 3α(β)-hydroxysteroid oxidoreductase in epithelium and stroma of human normal and hyperplastic prostate. J Clin Endocrinol Metab 71: 732-739
20. Tunn S, Schulze H, Krieg M (1993) 17β-hydroxysteroid oxidoreductase in epithelium and stroma of human prostate. J Steroid Biochem 46: 91-101
21. Krieg M, Weisser H, Tunn S (1995) Potential activities of androgen metabolizing enzymes in human prostate. J Steroid Biochem Molec Biol 53: 395-400
22. Kühnert B, Tunn S, Weisser H, Krieg M (1992) Influence of aging on androgen and progesterone receptor content in human benign prostatic hyperplasia. Urol Res 20: 443
23. Geller J (1990) Effect of finasteride, a 5α-reductase inhibitor on prostate tissue androgens and prostate-specific antigen. J Clin Endocrinol Metab 71: 1552-1555
24. Weisser H, Tunn S, Debus M, Krieg M (1994) 5α-reductase inhibition by finasteride (Proscar®) in epithelium and stroma of human benign prostatic hyperplasia. Steroids 59: 616-620
25. Rittmaster RS, Norman RW, Thomas LN, Rowden G (1996) Evidence for atrophy and apotosis in the prostates of men given finasteride. J Clin Endocrinol Metab 81: 814-819
26. Krieg M, Nass R, Tunn S (1993) Effect of aging on endogenous level of 5α-dihydrotestosterone, testosterone, estradiol and estrone in epithelium and stroma of normal and hyperplastic human prostate (BPH). J Clin Endocrinol Metab 77: 375-385
27. Weisser H, Tunn S, Behnke B, Krieg M (1996) Effects of the Sabal serrulata extract IDS 89 and its subfractions on 5α-reductase activity in human benign prostatic hyperplasia. Prostate 28: 300-306
28. Weisser H, Krieg M (1996) Lipid composition in epithelium and stroma of human benign prostatic hyperplasia. Prostate (in press)